Unfortunately, our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very, very strong balance sheet with huge value drivers at the end of it.
In most instances, biotechnology, though a radically different approach, is a sustaining technology: It's a dramatically improved way of targeting problems that we hadn't been able to solve with the conventional approach of mainstream pharmaceutical companies.
The trouble is the field of science, medicine, universities, biotech companies - you name it - have been so splintered, layers, sub-divided, hacked that people can spend their entire career studying one tiny little cog of life.
In chemicals, Synthetic Genomics is one of my real loves.
If I were 21 years old, I would go into biotechnology or genetic engineering.
Genetic engineering is having a serious impact on the food we eat, on the environment, and on farmers. To ensure we can maximize benefits and minimize hazards, Congress must provide a comprehensive regulatory framework for all genetically engineered products.
We're finding a third way for biologists to change the world. It's very hard to change the world when the only directions available in biology are academia and the pharmaceutical industry.
One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.
Monsanto can do anything they want to you, and put anything they want into your foods. There's nothing you can do about it.
It's a great disappointment as a leader in the biotech industry that with all the amazing things the drug industry has done in the last couple of decades, we have not made a single major advance, have not not developed a single new chemical entity approved for the treatment for Alzheimer's disease.
If only the human body could handle trauma as well as biotechnology stocks do.
It was a chance encounter with a biotech entrepreneur from Ireland that got me started as an entrepreneur in India, because I partnered this Irish company in setting up India's first biotech company.
One of the problems in the biotech world is the lack of women in leadership roles, and I'd like to see that change by walking the walk.
Business, life itself, is damned hard work if you wanna be good at it. Actually, that's precisely wrong. Business ceases to be work when you're chasing a dream that has engorged you. ("Work should be more fun than fun" - Noel Coward.) And if the passion isn't there. then biotech and plumbing will be equal drags.
What gets me pretty pissed off is the whole Monsanto engineered foods issue.
IndieBio's capital, facilities, and deep mentoring by a network of biotech-specific experts have the potential to spawn the Google, Facebook, and Instagrams of biology.
Hype tends to precede the reality in biotech, but the reality does follow. Usually.
The pace of progress in biology creates a foundation that naturally gets picked up by the biotech and pharmaceutical industry to solve rich-world diseases. This is attractive science. It's science that people want to work on.
Unfortunately in the U.S., the courts have pretty much sided with the GMO lobby and suggesting that a farmer has no rights to be protected from GMO contamination.
23andMe set out to try and change healthcare - this is not an easy business. This is not a coffee shop in Austin.
I am very passionate about India's place in bio-pharmaceuticals, and that is what I really want to drive and create leadership for in India because I really think it is possible.
